Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.32 |
| ▸ | BRAF | P15056 | 3/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991124 | 0.90 | CYP3A4 (0.35) | SLC6A9CYP3A4SCN9AHSD11B1NR1I2 | |
| SCHEMBL989778 | 0.87 | SLC6A9 (0.56) | SLC6A9CYP3A4HSD11B1NR1I2 | |
| SCHEMBL988888 | 0.86 | SLC6A9 (0.57) | SLC6A9CYP3A4HSD11B1POLB | |
| SCHEMBL988568 | 0.86 | CCR1 (0.37) | SLC6A9CYP3A4PSEN1PSEN2APH1B | |
| Hydrochloric Acid SCHEMBL988292 | 0.85 | SLC6A9 (0.56) | SLC6A9CYP3A4HSD11B1POLB | |
| SCHEMBL989660 | 0.83 | HSD11B1 (0.36) | SLC6A9CYP3A4SCN9AHSD11B1NR1I2 | |
| SCHEMBL988874 | 0.82 | HSD11B1 (0.36) | CYP3A4SCN9AHSD11B1NR1I2 | |
| SCHEMBL4263838 | 0.82 | SLC6A9 (0.52) | SLC6A9CYP3A4POLB | |
| SCHEMBL988940 | 0.82 | SLC6A9 (0.52) | SLC6A9CYP3A4HSD11B1POLB | |
| SCHEMBL989150 | 0.81 | SLC6A9 (0.48) | SLC6A9CYP3A4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2271625-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GOLT1B, SLC10A1, SUGT1 | SLC6A9 73/4885CYP3A4 328/4885PSEN1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.